- Home
- ACAD vs MHO Comparison
ACAD vs MHO Comparison
Compare ACAD & MHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- MHO
- Stock Information
- Founded
- ACAD 1993
- MHO 1976
- Country
- ACAD United States
- MHO United States
- Employees
- ACAD N/A
- MHO N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- MHO Homebuilding
- Sector
- ACAD Health Care
- MHO Consumer Discretionary
- Exchange
- ACAD Nasdaq
- MHO Nasdaq
- Market Cap
- ACAD 4.0B
- MHO 3.1B
- IPO Year
- ACAD 2004
- MHO 1986
- Fundamental
- Price
- ACAD $25.99
- MHO $147.36
- Analyst Decision
- ACAD Buy
- MHO Strong Buy
- Analyst Count
- ACAD 20
- MHO 3
- Target Price
- ACAD $28.63
- MHO $158.67
- AVG Volume (30 Days)
- ACAD 2.0M
- MHO 276.8K
- Earning Date
- ACAD 08-06-2025
- MHO 10-29-2025
- Dividend Yield
- ACAD N/A
- MHO N/A
- EPS Growth
- ACAD 615.00
- MHO N/A
- EPS
- ACAD 1.33
- MHO 18.23
- Revenue
- ACAD $1,018,885,000.00
- MHO $4,486,871,000.00
- Revenue This Year
- ACAD $14.01
- MHO N/A
- Revenue Next Year
- ACAD $11.72
- MHO $2.33
- P/E Ratio
- ACAD $19.61
- MHO $8.08
- Revenue Growth
- ACAD 14.41
- MHO 7.46
- 52 Week Low
- ACAD $13.40
- MHO $100.22
- 52 Week High
- ACAD $26.65
- MHO $176.18
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- MHO 70.98
- Support Level
- ACAD $25.14
- MHO $143.90
- Resistance Level
- ACAD $26.65
- MHO $147.37
- Average True Range (ATR)
- ACAD 0.67
- MHO 4.09
- MACD
- ACAD 0.04
- MHO 0.06
- Stochastic Oscillator
- ACAD 70.27
- MHO 93.40
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.